Replies to post #58114 on Avid Bioservices Inc (CDMO)

[entdoc]

frustrated, I share some of your feelings, but the reality is that uptown $80k/year is a give away for guys with huge talent...charity work...peanuts...a get together for guys devoted to the cause..all that. Not a huge number, 80k. It's true, not a lot of physical labor involved, but my guess is that they are worth it. And $80k is not even much dough for medium hitters in the rarified atomosphere of today's board directors. Look at what the competition offers.

[jessme]

I thought maybe the latest filing had to do with Medipharm/Medibiotech/CTL but the exhibits deal with Stason.

10.26 License Agreement between Stason Pharmaceuticals, Inc. and Peregrine Pharmaceuticals, Inc., dated May 3, 2010.**

10.27 Assignment Agreement between Stason Pharmaceuticals, Inc. and Peregrine Pharmaceuticals, Inc., dated May 3, 2010.**


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
October 26, 2010
ORDER GRANTING CONFIDENTIAL TREATMENT
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Peregrine Pharmaceuticals, Inc.
File No. 1-32839 - CF#25733
______________________
Peregrine Pharmaceuticals, Inc. submitted an application under Rule 24b-2
requesting confidential treatment for information it excluded from the Exhibits to a Form
10-Q filed on September 9, 2010.
Based on representations by Peregrine Pharmaceuticals, Inc. that this information
qualifies as confidential commercial or financial information under the Freedom of
Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined
not to publicly disclose it. Accordingly, excluded information from the following
exhibits will not be released to the public for the time periods specified:
Exhibit 10.26 through September 9, 2013
Exhibit 10.27 through September 9, 2013
For the Commission, by the Division of Corporation Finance, pursuant to
delegated authority:
Sonia Gupta Barros
Special Counsel